OJJAARA — 2189752
Application number
2189752
Registration number
TMA1339569
Type(s)
Standard Characters
Category
Trademark
CIPO Status
REGISTERED
TM5 status
LIVE/REGISTRATION/Issued
and Active
The trademark application has been registered with the Office.
Filed
2022-06-03
Registered
2025-08-15
Registration Expiry Date
2035-08-15
Registered Owner
GlaxoSmithKline LLC
Corporation Service Company
251 Little Falls Drive
Wilmington, DE 19808
UNITED STATES OF AMERICA
Agent
BORDEN LADNER GERVAIS LLP
World Exchange Plaza
100 Queen Street, Suite 1300
Ottawa
ONTARIO K1P1J9
Old Owner
Sierra Oncology LLC
Corporation Service Company
251 Little Falls Drive
Wilmington, DE 19808
UNITED STATES OF AMERICA
Documents
Index headings
- OJJAARA
Goods (Nice class & Statement)
- 5
- (1) Pharmaceutical preparations and drugs for the treatment of cancer, namely, Myelofibrosis (MF); pharmaceutical preparations and drugs for the treatment of cancer and tumors, treatment of blood diseases or disorders, bone and bone marrow diseases, and cancers associated with blood diseases or disorders; Biological preparations made from living tissues and human blood cells for the treatment of cancer; Pharmaceutical products, preparations, and compounds for the prevention and treatment of cancer and tumors, treatment of blood diseases or disorders, bone and bone marrow diseases, and cancers associated with blood diseases or disorders; Pharmaceutical preparations and substance for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Medical diagnostic reagents, assays, and test kits for testing of body fluids; DNA damage response assets, namely, pharmaceutical preparations for the treatment of conditions associated with DNA damage, namely cancer, for medical use.
Recordals (known also as Footnotes)
Owner Address Change / Changement d'adresse du propriétaire DATE REGISTERED / DATE DE L'ENREGISTREMENT: 2023-02-08 CHANGE IN TITLE / CHANGEMENT EN TITRE: TYPE OF CHANGE / GENRE DE CHANGEMENT: Name and Address / Nom et adresse DATE REGISTERED / DATE DE L'ENREGISTREMENT: 2023-02-16 DATE OF CHANGE / DATE DE CHANGEMENT: 2022-11-30 COMMENTS / COMMENTAIRES: FROM/DE: Sierra Oncology, Inc. TO/A: Sierra Oncology LLC CHANGE IN TITLE / CHANGEMENT EN TITRE: TYPE OF CHANGE / GENRE DE CHANGEMENT: Assignment / Cession DATE REGISTERED / DATE DE L'ENREGISTREMENT: 2023-03-20 DATE OF CHANGE / DATE DE CHANGEMENT: 2023-03-15 COMMENTS / COMMENTAIRES: FROM/DE: Sierra Oncology LLC TO/A: GlaxoSmithKline LLCAction History
| Action | Action date | Due date | Comments |
|---|---|---|---|
| Filed | 2022-06-03 | ||
| Created | 2022-06-03 | ||
| Formalized | 2022-06-03 | ||
| Pre-Assessment Letter Sent | 2022-07-20 | Retired Goods or Services | |
| Agent Changed | 2022-10-12 | From/De: 8390 To/A: 5153 | |
| Assignment Correspondence Created | 2023-02-01 | ||
| Amendment to Application | 2023-02-08 | Address/address | |
| Amendment to Application | 2023-02-16 | Name and Address/Nom et address | |
| Change of Title Registered | 2023-03-20 | Assignment/Cession | |
| Search Recorded | 2024-09-18 | ||
| Search Removed | 2024-09-19 | ||
| Search Recorded | 2024-09-19 | ||
| Search Removed | 2024-09-19 | ||
| Search Recorded | 2024-09-23 | ||
| Examiner's First Report | 2024-09-23 | 2025-03-23 | |
| Agent Changed | 2025-01-24 | From/De: 5153 To/A: 4 | |
| Approved | 2025-04-23 | APPROVED BY PROGRAM EX200M1 | |
| Approval Notice Sent | 2025-04-23 | APPROVED BY PROGRAM EX200M1 | |
| Advertised | 2025-05-28 | Vol.72 Issue 3683 | |
| Registration Pending | 2025-08-15 | ||
| Registered | 2025-08-15 | 2035-08-15 |